Life Science Nation Newsletter | April 4, 2019 | Issue 311

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
   Life Science Investor Mandates
(Mar. 28 - Apr. 3 )
Seeks Early Stage Therapeutic Partnerships in Cardiovascular, Metabolic Disease, Rare Diseases, and More
Considers All High Potential, Early-Stage Life Science Investment Opportunities
Invest in Life Science & Healthcare Technologies Addressing Prevention and Treatment of Chronic Diseases
Invests in Biotech & Medtech Opportunities, with Strong Interests in Platform Technologies
LSN Services
LSN Videos
LSN Media Partners
Mary Ann Picard
An interview with  Mary Ann Picard, COO of the M2D2 Incubator

- By  Greg Mannix, VP of International Business Development, LSN
Greg Mannix

One of the clear trends in Life Science funding is that investors are taking a keen interest in earlier and earlier-stage companies. Some investors will put money in at a very early stage, while others will come in a bit later, but what is very clear is that they all want to identify the most significant new technology breakthroughs in the life sciences and put those companies on their radar as soon as possible.

A majority of these hot, early-stage technologies are being developed in tech hubs all around the world. The Redefining Early-Stage Investments (RESI) conference series is an excellent opportunity for these Tech Hubs to gain visibility among investors who will want to track the technologies being incubated and accelerated in their facilities. This is why at LSN we have made a purposeful effort to create a nexus between these two key players in the life science ecosystem.

I recently spoke to Mary Ann Picard, COO at Massachusetts Medical Device Development (M2D2) Center about how RESI plays a part in the success of her program and its constituent companies.

Greg Mannix: First of all, I consider M2D2 a perfect example of a Tech Hub. Could you give me some context as to what M2D2 is?

Mary Ann Picard: M2D2 is an incubator program for medical device and biotech early stage startup companies. M2D2 is a joint project with UMass Lowell and UMass Medical School. No affiliation with UMass is required and no equity taken. Resident companies have access to a whole host of university resources and mentors...

Diana Saraceni
An interview with Diana Saraceni, Co-Founder & General Partner, Panakes Partners

- By Karen Deyo, Investor Research Analyst, LSN
Karen Deyo

One question that is commonly addressed during RESI panel sessions is: What should a company NOT do in initial meetings with investors? At RESI Europe, Diana Saraceni was a speaker on the Medical Device Investors panel and offered a list of six mistakes companies often make - some all the more important since they are mentioned less frequently. I spoke with Diana following RESI Europe, to recap this important advice. 

Karen Deyo (KD): Thank you again for speaking on the panel, Diana. Let us start with the more basic, well-known advice. What are some of the things companies do in discussions with you that send up red flags? 

Diana Saraceni (DS): One common issue we see is either too much or too little background information in an introductory pitch deck. On one hand, you do not need to spend several slides discussing what diabetes is, its prevalence and how it is currently treated. On the other hand, make sure to give an overview of the current standard-of-care, as a way to highlight what makes your technology unique. Another issue is a lack of flexibility with regards to valuation. Especially in early-stage, pre-revenue companies, even if they have received advice from a third party, this is never set in stone. You have to be open to negotiate with the investor, and remember that they and their experience are an added value for you...

By Jessica Yang, Sr. Investor Research Analyst & Asia BD, LSN

Taiwan is establishing its presence in the life science industry and becoming an important player on the global stage. As Taiwan moves ahead to build its life science innovative ecosystem, Life Science Nation has partnered with Ministry of Science and Technology (MOST) to organize an inaugural RESI Conference in Taipei, Taiwan on November 14th. RESI Taipei will be a great chance to get plugged into the Taiwan's rising life science ecosystem and meet emerging startups, both local and drawn from RESI's global network. 

Last month, the Taipei City Government, BTBA (Boston Taiwanese Biotechnology Association), and ITRI (Industrial Technology Research Institute) co-organized the "Taipei Bio Forum" event in Boston. As a media partner, LSN also promoted this event to invite life science industry players in Massachusetts. This event was a great chance to tap into Taipei's rapidly developing ecosystem of innovators and long-established network of sophisticated capital providers...

Created & Produced by